Published in Br J Cancer on June 01, 1996
Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res (2006) 1.65
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer (2008) 1.06
Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. Br J Cancer (2008) 0.94
A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer (2011) 0.92
Progress in personalizing chemotherapy for bladder cancer. Adv Urol (2012) 0.89
Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis (2013) 0.88
Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. Br J Cancer (1997) 0.87
Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology (1998) 0.86
Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther (2013) 0.85
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy. Clin Pharmacol Ther (2012) 0.83
Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo. Br J Cancer (1999) 0.83
Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Br J Cancer (2007) 0.83
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol (2010) 0.82
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Br J Cancer (2005) 0.81
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer. Br J Cancer (2003) 0.80
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol (2007) 0.80
Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines. J Pharm Sci (2016) 0.80
Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma. Br J Cancer (2005) 0.79
In silico modelling of treatment-induced tumour cell kill: developments and advances. Comput Math Methods Med (2012) 0.79
DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. Chem Res Toxicol (2016) 0.77
Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World J Gastroenterol (2006) 0.77
Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology. Chem Res Toxicol (2016) 0.75
Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. J Med Case Rep (2017) 0.75
Microdose-induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther (2016) 0.75
A Diagnostic Microdosing Approach to Investigate Platinum Sensitivity in Non-Small Cell Lung Cancer. Int J Cancer (2017) 0.75
Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol (1989) 6.86
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst (1994) 4.21
Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psychiatry (1979) 3.74
Drugs five years later. Cisplatin. Ann Intern Med (1984) 3.69
Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst (1994) 2.83
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol (1992) 2.27
Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry (1986) 2.09
Treatment of patients with cancer of an unknown primary site. N Engl J Med (1993) 2.00
Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med (1990) 1.99
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet (1992) 1.80
Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry (1988) 1.76
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A (1987) 1.71
Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst (1993) 1.66
Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res (1984) 1.43
The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis (1988) 1.38
Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm (1985) 1.36
Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest (1986) 1.35
Management of small-cell cancer of the lung. Lancet (1992) 1.35
Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology (1984) 1.35
Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol (1987) 1.32
Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res (1990) 1.19
A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol (1988) 1.16
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res (1993) 1.15
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (1991) 1.08
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res (1985) 1.07
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol (1987) 1.06
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer (1994) 1.03
Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res (1992) 1.03
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br J Cancer (1993) 1.03
Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer (1992) 1.02
Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol (1987) 1.02
Cisplatin in advanced cancer of the cervix: an update. Semin Oncol (1991) 0.99
Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol (1991) 0.96
Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ Health Perspect (1993) 0.96
Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J Clin Oncol (1989) 0.95
Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer (1990) 0.94
Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol (1994) 0.89
Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol (1987) 0.88
Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann Intern Med (1988) 0.88
Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther (1981) 0.87
Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adducts. Ann Oncol (1991) 0.87
DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res (1992) 0.85
High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol (1981) 0.83
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Br J Cancer (1995) 0.82
The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol (1992) 0.81
Dose intensity in germ cell tumors: lessons learned? J Natl Cancer Inst (1992) 0.77
The role of platinum dose intensity in the management of ovarian cancer. J Cancer Res Clin Oncol (1993) 0.76
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
CHARMM: the biomolecular simulation program. J Comput Chem (2009) 27.71
An STS-based map of the human genome. Science (1995) 17.72
GAL4-VP16 is an unusually potent transcriptional activator. Nature (1988) 16.53
A gene map of the human genome. Science (1996) 14.32
Deletion analysis of GAL4 defines two transcriptional activating segments. Cell (1987) 14.13
A physical map of 30,000 human genes. Science (1998) 12.43
Highly pathogenic H5N1 influenza virus infection in migratory birds. Science (2005) 9.64
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst (1996) 4.66
Purified ryanodine receptor from rabbit skeletal muscle is the calcium-release channel of sarcoplasmic reticulum. J Gen Physiol (1988) 4.56
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
The carboxy-terminal 30 amino acids of GAL4 are recognized by GAL80. Cell (1987) 4.49
A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med (1992) 4.25
Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial. BMJ (1998) 3.90
Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature (1997) 3.74
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA (1996) 3.69
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve (1991) 3.29
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (2002) 3.26
Generating yeast transcriptional activators containing no yeast protein sequences. Nature (1991) 3.21
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology (1998) 3.13
Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med (2001) 2.94
A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci (1999) 2.92
Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys (1999) 2.84
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab (1996) 2.78
Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr (2001) 2.64
Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res (2011) 2.64
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res (2001) 2.64
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
The superfamily of heme-copper respiratory oxidases. J Bacteriol (1994) 2.57
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol (2001) 2.52
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev (1992) 2.44
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Joint estimation of water/fat images and field inhomogeneity map. Magn Reson Med (2008) 2.35
Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res (1999) 2.30
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry (1998) 2.24
Prevalence of cryptosporidiosis in patients undergoing endoscopy: evidence for an asymptomatic carrier state. Am J Med (1989) 2.21
An HMG-like protein that can switch a transcriptional activator to a repressor. Nature (1994) 2.18
Surveillance of the first case of human avian influenza A (H7N9) virus in Beijing, China. Infection (2013) 2.18
Smoking cessation in China: findings from the 1996 national prevalence survey. Tob Control (2001) 2.10
Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer (1996) 2.06
Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis (1999) 2.06
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med (1990) 1.99
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol (1994) 1.97
Characterization of short tandem repeats from thirty-one human telomeres. Genome Res (1997) 1.96
FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet (1998) 1.96
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer (2001) 1.91
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88
An allosteric model of the molecular interactions of excitation-contraction coupling in skeletal muscle. J Gen Physiol (1993) 1.83
TSF3, a global regulatory protein that silences transcription of yeast GAL genes, also mediates repression by alpha 2 repressor and is identical to SIN4. Mol Cell Biol (1993) 1.82
A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J Natl Cancer Inst (1985) 1.79
Printable thin film supercapacitors using single-walled carbon nanotubes. Nano Lett (2009) 1.79
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet (1984) 1.77
A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol (1997) 1.76
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Meta-analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. Br J Surg (1990) 1.75
Mitochondrial depolarization accompanies cytochrome c release during apoptosis in PC6 cells. J Biol Chem (1999) 1.75
Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst (1998) 1.74
Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology (1996) 1.74
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
High prevalence of bla(CTX-M) extended-spectrum β-lactamase genes in Escherichia coli isolates from pets and emergence of CTX-M-64 in China. Clin Microbiol Infect (2010) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. J Inorg Biochem (2003) 1.66
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol (1995) 1.61
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell (1997) 1.60
The Drosophila morphogenetic protein Bicoid binds DNA cooperatively. Development (1996) 1.59
Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett (2001) 1.58
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol (1996) 1.58
Role of formulation vehicles in taxane pharmacology. Invest New Drugs (2001) 1.58
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57